ILMN:NGS-Illumina Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 122.28

Change

+1.23 (+1.02)%

Market Cap

USD 19.79B

Volume

0.83M

Analyst Target

USD 347.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-26 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.39 (+0.70%)

USD 41.47B
ICLR ICON PLC

-2.79 (-0.89%)

USD 25.49B
MEDP Medpace Holdings Inc

-14.49 (-3.60%)

USD 12.27B
NTRA Natera Inc

-1.49 (-1.53%)

USD 11.20B
EXAS EXACT Sciences Corporation

-1.93 (-3.14%)

USD 10.68B
RDNT RadNet Inc

-1.84 (-3.51%)

USD 3.57B
SHC Sotera Health Co

-0.26 (-2.22%)

USD 3.10B
OLK Olink Holding AB ADR

+0.25 (+1.08%)

USD 2.72B
NEOG Neogen Corporation

-0.36 (-2.90%)

USD 2.63B
GH Guardant Health Inc

-0.18 (-0.96%)

USD 1.96B

ETFs Containing ILMN

CURE:XETRA VanEck Genomics and Healt.. 6.18 % 0.00 %

-0.13 (0.00%)

USD 6.89M
CURG:LSE VanEck Genomics and Healt.. 4.70 % 0.00 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 4.32 % 0.00 %

-0.20 (0.00%)

USD 5.39M
DDOC:F Global X Telemedicine & D.. 4.32 % 0.00 %

-0.06 (0.00%)

USD 5.39M
EDOC:SW Global X Telemedicine & D.. 4.28 % 0.00 %

-0.10 (0.00%)

USD 4.92M
EDOG:LSE Global X Telemedicine & D.. 4.12 % 0.00 %

-0.17 (0.00%)

USD 0.68M
XGEN:XETRA Xtrackers MSCI Genomic He.. 4.02 % 0.00 %

-0.07 (0.00%)

USD 3.51M
GN0M:XETRA Global X Genomics & Biote.. 3.81 % 0.00 %

-0.05 (0.00%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.60 % 0.00 %

-0.01 (0.00%)

USD 6.73M
GNOG:LSE Global X Genomics & Biote.. 3.56 % 0.00 %

-0.04 (0.00%)

USD 6.47M
CDNA:CA CI Bio-Revolution ETF 3.35 % 0.00 %

N/A

CAD 4.55M
BTEC:SW iShares Nasdaq US Biotech.. 2.15 % 0.00 %

-0.04 (0.00%)

USD 0.46B
BTEC:LSE iShares Nasdaq US Biotech.. 2.09 % 0.00 %

-0.02 (0.00%)

USD 0.46B
BTEK:LSE iShares Nasdaq US Biotech.. 2.09 % 0.00 %

+0.01 (+0.00%)

USD 0.52B
BTEE:LSE iShares Nasdaq US Biotech.. 2.09 % 0.00 %

-0.02 (0.00%)

USD 0.52B
ROBO:SW L&G ROBO Global Robotics .. 1.79 % 0.00 %

+0.04 (+0.00%)

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

-0.01 (0.00%)

USD 1.24B
ALFA 0.00 % 0.65 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

-0.36 (0.00%)

USD 0.41B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

-0.65 (0.00%)

USD 0.08B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.16 (+0.00%)

USD 3.52M
IBB iShares Biotechnology ETF 0.00 % 0.47 %

-0.69 (0.00%)

USD 6.95B
IBCE 0.00 % 0.10 %

N/A

N/A
IBDD 0.00 % 0.10 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.08 (0.00%)

USD 0.09B
ZBIO 0.00 % 0.95 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

-0.02 (0.00%)

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

-0.26 (0.00%)

USD 0.05B
BBIG:CA 0.00 % 0.00 %

N/A

N/A
QQEQ:CA Invesco NASDAQ 100 Equal .. 0.00 % 0.00 %

-0.11 (0.00%)

CAD 3.70M
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

-0.15 (0.00%)

USD 0.03B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -12.18% 60% D- 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.18% 60% D- 34% F
Trailing 12 Months  
Capital Gain -40.51% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.51% 40% F 23% F
Trailing 5 Years  
Capital Gain -61.06% 48% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -61.06% 48% F 21% F
Average Annual (5 Year Horizon)  
Capital Gain -10.33% 41% F 27% F
Dividend Return -10.33% 41% F 26% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.51% 86% B+ 55% F
Risk Adjusted Return -30.83% 36% F 27% F
Market Capitalization 19.79B 96% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 45.90 17% 12%
Price/Book Ratio 3.80 33% 29%
Price / Cash Flow Ratio 45.72 8% 6%
Price/Free Cash Flow Ratio -37.87 96% 93%
Management Effectiveness  
Return on Equity -18.81% 71% 45%
Return on Invested Capital -13.44% 73% 37%
Return on Assets -0.53% 86% 58%
Debt to Equity Ratio 25.92% 57% 55%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector